DMAC (DiaMedica Therapeutics) Preferred Dividends: $0.00 Mil (TTM As of Mar. 2026)


DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $7.61
! 2 Warning Signs
View Full Analysis

What is DiaMedica Therapeutics Preferred Dividends?

DiaMedica Therapeutics DMAC +2.35% 31 Preferred Dividends is $0.00 Mil as of Mar. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. DiaMedica Therapeutics's preferred dividends for the three months ended in Mar. 2026 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

DiaMedica Therapeutics  (NAS:DMAC) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Preferred Dividends Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Preferred Dividends Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Preferred Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DiaMedica Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Preferred Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Frequently Asked Questions Learn more about Preferred Dividends →
What does a Preferred Dividends of $0.00 Mil mean?
DiaMedica Therapeutics (DMAC) has a Preferred Dividends of $0.00 Mil as of Mar. 2026. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Preferred Dividends too high?
DiaMedica Therapeutics' current Preferred Dividends is $0.00 Mil. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Preferred Dividends compare to PRLD and RCKT?
DiaMedica Therapeutics' Preferred Dividends of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Dividends for a Biotechnology company?
A good Preferred Dividends depends on the Biotechnology industry context. However, Preferred Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Dividends mean?
A high Preferred Dividends can signal that a stock is expensive relative to its fundamentals. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Preferred Dividends is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Preferred Dividends of $0.00 Mil. The current Preferred Dividends is $0.00 Mil. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Dividends calculated?
Preferred Dividends is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Preferred Dividends is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Preferred Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.61
Price